INVA Research and Charts

INVA - Innoviva Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-07-11)

Last 18.77	Change ⇓ -0.29 (-1.52%)	Volume 764,766
	Open 19.40	High 19.40	Low 18.75

8EMA (Daily) 19.25	40EMA (Daily) 19.75	50EMA (Daily) 19.64	STO (Daily) 4.768	MACD Hist (Daily) -0.415
8EMA (Weekly) 19.639	40EMA (Weekly) 18.68	50EMA (Weekly) 18.43	STO (Weekly) 64.998	MACD Hist (Weekly) -0.024


Company Profile
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.